股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/註冊 ...

智通财经APP获悉，新达控股(08471)、康圣环球(09960)于2026年1月30日进行了最新股东权益披露。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 新达控股(08471) | 肖丰岑 | 好仓 | 1.55 亿股 | 5477.00 万股 | 4.46%(最新) 12.62%(前次) | | 康圣环球(09960) | Mialkos Tomasz | 好仓 | 8292.35 万股 | 8330.85 万股 | 8.00%(最新) | | | Jakub | | | | 7.96%(前次) | 备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 ...

Group 1 - The core point of the news is that Mialkos Tomasz Jakub increased his stake in Kangsheng Global (09960.HK) by purchasing 385,000 shares at an average price of HKD 1.212 per share, resulting in a total investment of approximately HKD 466,600 [1] - After the purchase, Mialkos Tomasz Jakub's total shareholding increased to 83,308,500 shares, raising his ownership percentage from 7.96% to 8.00% [1][2]

Kindstar Globalgene Technology, Inc. 有關收購華西康聖達40%股權之關連交易之 補充公告 茲提述本公司日期為2025年11月25日之公告（「該公告」），內容有關收購華西康聖 達40%股權。除文義另有所指外，本公告所用詞彙與該公告所界定者具有相同涵 義。本公告旨在就收購華西康聖達40%股權之關連交易提供進一步資料。 量化指標的假設 康聖環球基因技術有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：9960） 以下為量化指標的假設。預測期取5年，即2025年至2029年。以後年度收益趨於 穩定，並假定與2029年相同（「穩定期」）。 收入增長率 華西康聖達主要客戶為合作醫院及其他第三方檢驗機構，通過提供血液、腫瘤等 特檢服務獲取收入。華西康聖達2020年至2024年的年均收入增長率約為5.45%。 受經濟形勢影響，2024年收入出現下降趨勢。為應對挑戰，2025年， ...

致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 本月底法定/註 ...

Core Insights - The 67th American Society of Hematology Annual Meeting (ASH 2025) took place from December 6 to 9 in Orlando, showcasing advancements in hematology and attracting global experts [1][15] - Kangsheng Global Group, a leading Chinese diagnostic company specializing in hematology, presented its capabilities in precision diagnosis, companion diagnostics, and laboratory services at booth 1181 [1][15] Group 1: Event Highlights - The Kangsheng booth attracted numerous international visitors, facilitating discussions on CAR-T therapy optimization, CRISPR gene editing applications, minimal residual disease (MRD) monitoring, and standardization of molecular diagnostics in hematology [1][14] - The atmosphere at the conference was vibrant, with deep dialogues among top experts, pharmaceutical R&D leaders, and representatives from biotech companies and CROs [1][14] Group 2: Business Focus - Haixi Bio, a specialized platform under Kangsheng, showcased its comprehensive product system in fusion gene testing, targeted gene panels, and automated bioinformatics analysis, gaining significant attention from international peers [3][17] - Kangsheng established direct communication channels with several globally renowned pharmaceutical and biotech companies during the conference, aiming to build an efficient international collaboration network [5][19] Group 3: Research Contributions - Multiple research findings from Kangsheng were selected for poster presentations at ASH 2025, highlighting the company's depth in research and clinical value in precision medicine for hematological malignancies [7][21] - Research 4972 analyzed immune gene rearrangements in 79 Chinese multiple myeloma patients, revealing a strong correlation between Ig clone proportions and treatment efficacy, with a new prognostic model showing high discrimination (AUC=0.988) [21][22] - Research 1929 proposed a novel strategy to reverse CAR-T cell exhaustion in PD-L1 high large B-cell lymphoma, demonstrating enhanced proliferation and anti-tumor function through a combination of IL-7/CCL19 armored CAR-T cells and timed PD-1 blockade [22][10] - Research 5778 utilized targeted capture sequencing to identify driver mutations in 101 newly diagnosed multiple myeloma patients, constructing an accurate prognostic model that outperformed traditional staging systems [24][12] Group 4: Future Directions - Despite the conclusion of ASH 2025, the pursuit of innovation in hematology continues, with Kangsheng committed to leveraging its technological expertise and network to enhance international cooperation and align precision diagnostic technologies with clinical needs [15][28]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/ ...

Core Viewpoint - The company has successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for RMB 12.396 million, enhancing its strategic control over the regional high-end medical testing services in Southwest China [1] Group 1: Transaction Details - Wuhan Kangshengda has successfully won the bid for a 40% stake in Huaxi Kangshengda through the North Exchange public listing process [1] - The transaction was formalized on November 25, 2025, with a total consideration of RMB 12.396 million [1] - Following the completion of this transaction, Huaxi Kangshengda will become a wholly-owned subsidiary of the company [1] Group 2: Strategic Benefits - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the Southwest region, covering Sichuan, Chongqing, Yunnan, and Guizhou [1] - The acquisition will enhance the company's management and strategic direction over Huaxi Kangshengda, ensuring efficient and consistent execution of the overall strategy in the Southwest region [1] - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergistic effects between ICL-driven IVD product development and IVD service upgrades [1] Group 3: Management and Collaboration - The company will take full control over the management appointments, performance assessments, and resource allocation of Huaxi Kangshengda, improving the execution efficiency of cross-regional projects [1] - The company aims to deepen its clinical and research collaboration with Sichuan University Huaxi Hospital, integrating channels, technology, and medical resources in the Southwest region [1] - This integration will strengthen the regional operational capabilities of the company [1]

Core Viewpoint - The company successfully acquired a 40% stake in Huaxi Kangshengda, enhancing its strategic position in the southwestern region of China and aligning with its overall business strategy [1] Group 1: Acquisition Details - Wuhan Kangshengda has successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for a consideration of RMB 12.396 million [1] - Following the completion of this transaction, Huaxi Kangshengda will become a wholly-owned subsidiary of the company [1] Group 2: Strategic Benefits - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the southwestern region, providing high-end special inspection services across Sichuan, Chongqing, Yunnan, and Guizhou [1] - The acquisition will strengthen the company's management over Huaxi Kangshengda's operations and strategic direction, ensuring efficient and consistent execution of the overall strategy in the southwestern region [1] Group 3: Operational Enhancements - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergies between ICL-driven IVD product development and IVD service upgrades [1] - The company will take full control of Huaxi Kangshengda's management appointments, performance assessments, and resource allocation, enhancing the execution efficiency of cross-regional projects [1] - The company aims to deepen its clinical and research collaboration with Sichuan University Huaxi Hospital, integrating channels, technology, and medical resources in the southwestern region to strengthen regional integrated operational capabilities [1]

Core Viewpoint - The acquisition of a 40% stake in Huaxi Kangshengda by Wuhan Kangshengda is a strategic move to enhance the company's control over its operations and align with its overall business strategy in the southwestern region of China [1][2]. Group 1: Transaction Details - Wuhan Kangshengda successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for a consideration of RMB 12.396 million [1]. - Following the completion of this transaction, Huaxi Kangshengda will become an indirect wholly-owned subsidiary of the company [2]. Group 2: Strategic Importance - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the southwestern region, providing high-end special inspection services across Sichuan, Chongqing, Yunnan, and Guizhou [2]. - The full ownership will enhance the company's management and strategic direction over Huaxi Kangshengda, ensuring efficient execution of the overall strategy in the southwestern region [2]. - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergy between ICL-driven IVD product development and IVD service upgrades [2].